Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48. https://doi.org/10.3322/caac.21763.
Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint Blockade. Science. 2018;359:1350–5. https://doi.org/10.1126/science.aar4060.
Schumacher TN, Thommen DS. Tertiary lymphoid structures in cancer. Science. 2022;375:eabf9419. https://doi.org/10.1126/science.abf9419.
Hugaboom MB, Wirth LV, Street K, Ruthen N, Jegede OA, Schindler NR, Shah V, Zaemes JP, El Ahmar N, Matar S, et al. Presence of tertiary lymphoid structures and exhausted Tissue-Resident T cells determines clinical response to PD-1 Blockade in renal cell carcinoma. Cancer Discov. 2025;15:948–68. https://doi.org/10.1158/2159-8290.CD-24-0991.
Zhang E, Ma Y, Liu Z, Zhang J, Liu W, Chen Y, Liu G, Liu X, Zhang F, Zhu Y, et al. Prognostic implications and characterization of tumor-associated tertiary lymphoid structures genes in pancreatic cancer. J Transl Med. 2025;23:301. https://doi.org/10.1186/s12967-025-06152-8.
Pradhan M, Kildal W, Vlatkovic L, Tobin KAR, Lindemann K, Kristensen GB, Kleppe A, Askautrud HA. Prognostic value of tertiary lymphoid structures in molecular subgroups of endometrial carcinoma. Int J Gynecol Cancer. 2025;35:101915. https://doi.org/10.1016/j.ijgc.2025.101915.
Mi Z, Chen J, Zhang Z, Liu J, Lei Y, Tan H, Li W, Chen X, Rong P. Synthetic biology-driven induction of mature TLS formation enhances antitumor immunity in colorectal cancer. Sci Transl Med. 2025;17: eado8395. https://doi.org/10.1126/scitranslmed.ado8395.
Su X, Kang D, Wang J, Li L, Huang R, Zou Z. Tertiary lymphoid structures associated with improved survival and enhanced antitumor immunity in acral melanoma. NPJ Precis Oncol. 2025;9:103. https://doi.org/10.1038/s41698-025-00891-z.
Su J-Y, Li J-R, Pan L-X, Ma Y-L, Tian W, Jiang Y-M, Guo P-P, Li L, Deng Z-J, Li Z-Z, et al. Tertiary lymphoid structures in hepatocellular carcinoma: influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy. Hepatology. 2025. https://doi.org/10.1097/HEP.0000000000001433.
Guo Z, Feng H, Jia W, Zhang T, Chen M, Xu Z, Zheng F, Huang C, Li Z, Liu K, et al. Tertiary lymphoid structures signature predicts prognosis and clinical benefits from adjuvant chemotherapy and PD-L1 Blockade in colorectal adenocarcinoma. Int J Surg. 2025. https://doi.org/10.1097/JS9.0000000000002568.
Teillaud J-L, Houel A, Panouillot M, Riffard C, Dieu-Nosjean M-C. Tertiary lymphoid structures in anticancer immunity. Nat Rev Cancer. 2024;24:629–46. https://doi.org/10.1038/s41568-024-00728-0.
Munoz-Erazo L, Rhodes JL, Marion VC, Kemp RA. Tertiary lymphoid structures in cancer – considerations for patient prognosis. Cell Mol Immunol. 2020;17:570–5. https://doi.org/10.1038/s41423-020-0457-0.
Sautès-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307–25. https://doi.org/10.1038/s41568-019-0144-6.
Sun X, Liu W, Sun L, Mo H, Feng Y, Wu X, Li C, Chen C, Li J, Xin Y, et al. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2022;10:e005531. https://doi.org/10.1136/jitc-2022-005531.
Xin S, Wen S, He P, Zhao Y, Zhao H. Density of tertiary lymphoid structures and their correlation with prognosis in non-small cell lung cancer. Front Immunol. 2024;15:1423775. https://doi.org/10.3389/fimmu.2024.1423775.
He M, He Q, Cai X, Liu J, Deng H, Li F, Zhong R, Lu Y, Peng H, Wu X, et al. Intratumoral tertiary lymphoid structure (TLS) maturation is influenced by draining lymph nodes of lung cancer. J Immunother Cancer. 2023;11:e005539. https://doi.org/10.1136/jitc-2022-005539.
Hayashi Y, Makino T, Sato E, Ohshima K, Nogi Y, Kanemura T, Honma K, Yamashita K, Saito T, Tanaka K, et al. Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors. Br J Cancer. 2023;128:2175–85. https://doi.org/10.1038/s41416-023-02235-9.
Xu F, Zhu H, Dong Y, Li L, Liu N, Yuan S. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy. Front Immunol. 2023;14:1244256. https://doi.org/10.3389/fimmu.2023.1244256.
Bod L, Kye Y-C, Shi J, Torlai Triglia E, Schnell A, Fessler J, Ostrowski SM, Von-Franque MY, Kuchroo JR, Barilla RM, et al. B-cell-specific checkpoint molecules that regulate anti-tumour immunity. Nature. 2023. https://doi.org/10.1038/s41586-023-06231-0.
Xie M, Lin X, Bao X, Liang Y, Deng H, Song J, Ma X, Zhang X, Yao J, Pan L, et al. Tertiary lymphoid structure in tumor microenvironment and immunotherapy of lung cancer. Arch Bronconeumol. 2024;60(Suppl 2):S77–85. https://doi.org/10.1016/j.arbres.2024.07.020.
Wang Y, Lin H, Yao N, Chen X, Qiu B, Cui Y, Liu Y, Li B, Han C, Li Z, et al. Computerized tertiary lymphoid structures density on H&E-images is a prognostic biomarker in resectable lung adenocarcinoma. iScience. 2023;26:107635. https://doi.org/10.1016/j.isci.2023.107635.
Chen Z, Wang X, Jin Z, Li B, Jiang D, Wang Y, Jiang M, Zhang D, Yuan P, Zhao Y, et al. Deep learning on tertiary lymphoid structures in hematoxylin-eosin predicts cancer prognosis and immunotherapy response. NPJ Precis Oncol. 2024;8:73. https://doi.org/10.1038/s41698-024-00579-w.
Fukuhara M, Muto S, Inomata S, Yamaguchi H, Mine H, Takagi H, Ozaki Y, Watanabe M, Inoue T, Yamaura T, et al. The clinical significance of tertiary lymphoid structure and its relationship with peripheral blood characteristics in patients with surgically resected non-small cell lung cancer: a single-center, retrospective study. Cancer Immunol Immunother. 2022;71:1129–37. https://doi.org/10.1007/s00262-021-03067-3.
Dieu-Nosjean M-C, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26:4410–7. https://doi.org/10.1200/JCO.2007.15.0284.
Wu X, Huang Q, Chen X, Zhang B, Liang J, Zhang B. B cells and tertiary lymphoid structures in tumors: immunity cycle, clinical impact, and therapeutic applications. Theranostics. 2025;15:605–31. https://doi.org/10.7150/thno.105423.
Tian X, Zheng X, Tian D. B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy. Sig Transduct Target Ther. 2023;8:1–2. https://doi.org/10.1038/s41392-023-01643-w.
Balan S, Saxena M, Bhardwaj N. Dendritic cell subsets and locations. Int Rev Cell Mol Biol. 2019;348:1–68. https://doi.org/10.1016/bs.ircmb.2019.07.004.
Baba T, Ishizu A, Iwasaki S, Suzuki A, Tomaru U, Ikeda H, Yoshiki T, Kasahara M. CD4+/CD8 + macrophages infiltrating at inflammatory sites: a population of monocytes/macrophages with a cytotoxic phenotype. Blood. 2006;107:2004–12. https://doi.org/10.1182/blood-2005-06-2345.